Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment of Sever Acne

This study has been completed.

Sponsor:

Information provided by:

Shaheed Beheshti Medical University

ClinicalTrials.gov Identifier:

NCT00416585

First received: December 27, 2006

Last updated: January 22, 2008

Last verified: January 2008

History of Changes

Tracking Information

First Received Date ^ICMJE

December 27, 2006

Last Updated Date

January 22, 2008

Start Date ^ICMJE

October 2005

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

serum levels of Ca, P, PTH and vitamin D metabolites and lateral chest x-ray before the treatment

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00416585 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

serum levels of Ca, P, PTH and vitamin D metabolites and lateral chest x-ray after the treatment

Original Secondary Outcome Measures ^ICMJE

Same as current

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment of Sever Acne

Official Title ^ICMJE

Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment

Brief Summary

serum levels Ca, P, PTH and vitamin D metabolites before and after treatment with isotretinoin for sever acne

Detailed Description

few studies has been done of serum levels Ca, P, PTH and vitamin D metabolites in patients receiving isotretinoin .In this study we measured serum levels Ca, P, PTH and vitamin D metabolites before and after treatment with isotretinoin for sever acne in 30 patients . the patients had no kown skeletal, endocrine ,renal and gastrointestinal disorders.

Study Type ^ICMJE

Interventional

Study Phase

Phase 1

Study Design ^ICMJE

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Condition ^ICMJE

Acne

Intervention ^ICMJE

Drug: isotretinoin (Roaccutane)

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

November 2006

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

sever acne

Exclusion Criteria:

renal disorders
gastrointestinal disorders
skeletal disorders
endocrine disorders
drugs such as glucocorticoids , thiazide diuretics, mineral multivitamins, anti acids, tetracyclines

Gender

Both

Ages

Not Provided

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Iran, Islamic Republic of

Administrative Information

NCT Number ^ICMJE

NCT00416585

Other Study ID Numbers ^ICMJE

src-hmnm-1385

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Shaheed Beheshti Medical University

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Study Chair:	parviz toossi, md	Skin Research Center
Principal Investigator:	Hamideh Moravvej, md	Skin Research Center
Principal Investigator:	Nahid Mohtasham, md	Skin Research Center

Information Provided By

Shaheed Beheshti Medical University

Verification Date

January 2008

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top